Emilie Wang, M.D.

Board eligible Hematology/Oncology
Image of Emilie Wang, M.D.
Emilie Wang, M.D. has joined the Cancer Center of Sarasota-Manatee, a member of the MAXhealth  family of physicians and services.  She will see be seeing patients at the Sarasota office located at 3830 Bee Ridge Road.

A native Floridian, Dr. Wang completed her Hematology/Oncology Fellowship at Moffitt Cancer Center and her Internal Medicine Residency at the University of South Florida . She received her medical degree from the Florida State University College of Medicine .

Dr. Wang is joining our Cancer Center as a Hematology/Oncology specialist and brings with her a passion for medicine, patient care, and research. She has been a contributor in numerous research publications and clinical trials as well as held leadership roles in academic groups. Dr. Wang is a member of the American Society of Clinical Oncology , the American Society of Hematology , the American College of Physicians , and the American Medical Association .

During her free time, Dr. Wang enjoys traveling, unique culinary experiences, and spending time with her family. She believes in personable and tailored care that aligns with her patients’ goals. She is on staff at Sarasota Memorial Hospital , Doctor’s Hospital , Manatee Memorial Hospital , and Blake Medical Center .

Education

July 2018 – June 2021
Hematology Oncology Fellowship, University of South Florida/Moffitt Cancer Center, Tampa, FL
July 2015 – June 2018
Internal Medicine Residency, University of South Florida, Tampa, FL
June 2011 – May 2015
Doctor of Medicine, Florida State University College of Medicine, Tallahassee, FL
August 2005 – May 2009
Bachelor of Science in Biology, Economics, Chemistry, Magna Cum Laude, University of Miami, Coral Gables, FL

Licensure

2015 Florida Licensure

Memberships

2016 – present
American Society of Clinical Oncology
2016 – present
American Society of Hematology
2013 – present
American College of Physicians
2013 – present
American Medical Association

Hospitals

Doctors Hospital, Sarasota
Blake Hospital, Bradenton

Pending Hospital Privileges

Sarasota Memoral Hospital, Sarasota
Manatee Memorial Hiospital, Bradenton

Publications

Kim R, Tan E, Wang E, Mahipal A, Chen D, Cao B, Masawi F, Machado C, Yu J, Kim D. Phase I Study of Trametinib Combined with Sorafenib in Patients with Advanced Hepatocellular Cancer (HCC). The Oncologist. 2020 Dec; 25(12).

Wang E, Haider M, Sokol L. Aggressive Natural Killer Cell Leukemia. Hematologic Malignancies. Eds Sallman D, Chaundhury A, Nguyen J, Zhang L, List A. New York: Springer Publishing Company, 2020.

Wang E, Chaundhury A, Pinilla-Ibarz J. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Hematologic Malignancies. Eds Sallman D, Chaundhury A, Nguyen J, Zhang L, List A. New York: Springer Publishing Company, 2020.

Wang E, Zhang X, Sokol L, Zhang L. Clinical Manifestation and Management of Aggressive NK Cell Leukemia. Benign and Malignant Disorders of Large Granular Lymphocytes. Eds Zhang L, Sokol L. New York: Nova, 2019. 265-278.

Kim R, Coppola D, Wang E, Chang YD, Kim Y, Anaya D, Kim DW. Prognostic Value of CD8CD45RO Tumor Infiltrating Lymphocytes in Patients with Extrahepatic Cholangiocarcinoma. Oncotarget. 2018 May 4; 9(34):23366-23372.

Eatrides J, Wang E, Kothari N, Kim R. Role of Systemic Therapy & Future Directions for Hepatocellular Carcinoma. Cancer Control Journal. 2017 Jul-Sep;24(3).

Hicks JK, Saller J, Wang E, Boyle T, Gray J. Cases Studies of Discordant Molecular Results in Lung Cancer: Implications for Precision Medicine and Methods for Resolving Conflicting Actionable Results. Lung Cancer. 2017 Sep;111:135-138.

Wang E, Karedan T, Perez C. New Insights in the Treatment of Radioiodine Refractory Differentiated Thyroid Carcinomas: To Lenvatinib and Beyond. Anti-Cancer Drugs 2015:26(7):689-697.

Westin GF, Perez CA, Wang E, Glück S. Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers 2013 Aug 29;28(3):233-241.

Ahn E, Wang E, Glück S. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer: Basic and Clinical Research 2012:6 191-207.


Sarasota: 3830 Bee Ridge Road, Suite 301, Sarasota, FL 34233 | (941)923.1872
Bradenton: 4351 Cortez Road, Suite 100, Bradenton, FL 34210 | (941)755.0606
©2021 Cancer Center of Sarasota-Manatee. All Rights Reserved.